AstraZeneca partners with Oxford Biomedica to expand COVID-19 vaccine manufacturing capacity

(Reuters) - AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine, as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.The deal comes a week after the United States secured almost a third of the first 1 billion doses planned for the vaccine, which has now moved to larger human trials in the global race to crack a solution to the coronavirus crisis.The experimental shot is also being produced..